By Fineline Cube 
AstraZeneca plc (NYSE: AZN) announced positive results from a pre-specified interim analysis of the Phase III I CAN trial, demonstrating that Ultomiris (ravulizumab) achieved a statistically significant and clinically meaningful reduction in proteinuria at 34 weeks in adult patients with IgA nephropathy (IgAN) at risk of disease progression.
Clinical Trial Highlights
| Endpoint | Measurement | Result |
|---|---|---|
| Primary Endpoint 1 | 24-hour urine protein-to-creatinine ratio (UPCR) at 34 weeks | Statistically significant and clinically meaningful reduction |
| Primary Endpoint 2 | Change from baseline in estimated glomerular filtration rate (eGFR) | To be measured at 106 weeks |
| Patient Population | Adults with IgA nephropathy at risk of disease progression | — |
| Trial Design | Phase III, randomized, double-blind, placebo-controlled | — |
Drug Mechanism & Profile
- Molecule: Ravulizumab (Ultomiris)
- Class: Longest-acting C5 complement inhibitor available
- Mechanism: Inhibits the C5 protein in the terminal complement cascade, preventing the immune system from overreacting and attacking healthy cells
- Key Benefit: Provides immediate, complete, and sustained complement inhibition with less frequent dosing compared to first-generation inhibitors
Regulatory Status & Commercial Potential
Ultomiris is already approved in major markets including the U.S., EU, Japan, and China for multiple indications:
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Atypical hemolytic uremic syndrome (aHUS)
- Generalized myasthenia gravis (gMG)
- Neuromyelitis optica spectrum disorder (NMOSD)
The successful interim results in IgA nephropathy could significantly expand Ultomiris’ addressable market, as IgAN affects an estimated 100,000+ patients in the U.S. and EU alone, with no approved targeted therapies currently available.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory approvals, and commercial potential for Ultomiris. Actual outcomes may differ based on final trial results, regulatory decisions, and competitive developments.-Fineline Info & Tech